Abstract 101P
Background
Immunotherapy has become a standard of care for recurrent and metastatic cervical carcinoma resulting in the need to carefully assess for surrogacy focusing on new therapeutic scenarios. This study delves into a systematic review and meta-analysis to unravel the potential of progression-free survival (PFS) as a surrogate endpoint in cervical cancer.
Methods
We performed a comprehensive search of randomized phase 2 and 3 clinical trials in advanced and recurrent cervical cancer. PRISMA guidelines were followed, and the study was registered in PROSPERO (CRD42023405604). Inclusion criteria required RCTs with mature PFS and OS data. Trials with adjuvant treatment or disease-free survival as primary endpoint were excluded. Subgroup analysis was performed by type of treatment (i.e. chemotherapy-based, chemo-immunotherapy combinations).
Results
11,348 articles were screened, and 31 included in the final analysis. In the overall population, a robust correlation between PFS and OS was observed (Spearman's rho = 0.66, p-value < 0.001). We calculated the Surrogate Threshold Effect (STE) at the PFS intersection with null OS outcome (p = 0.05), resulting in a threshold for PFS z-score (z-PFS) of 2.23. When examining the results by treatment modality, chemotherapy trials exhibited a notably weak and non-significant correlation (Spearman 0.34, p = 0.31) with a significantly higher STE (z-PFS = 2.92). Conversely, in chemo-immunotherapy combinations, the correlation was notably robust and statistically significant (Spearman 0.94, p = 0.017), associated with a considerably lower STE (z-PFS = 2.1).
Conclusions
PFS may serve as a surrogate endpoint in cervical cancer. Notably, PFS was a more promising surrogate marker in the context of chemo-immunotherapy when compared to chemotherapy alone. This aligns with the hypothesis that chemo-immunotherapy induces a response, which is further sustained through maintenance immunotherapy, thereby enabling PFS to better capture the impact on OS. Conversely, in chemotherapy-based treatments, the expected survival benefit may be more limited, and PFS may not as strongly capture the effect of chemotherapy alone.
Legal entity responsible for the study
European Organisation for Research and Treatment of Cancer (EORTC), Young Gynaecological Cancer Group.
Funding
Has not received any funding.
Disclosure
F. Herrera: Financial Interests, Institutional, Research Grant, Grant/Research Support: Accuracy Inc, Bioprotext, BMS, Roche-ImFlame/ImCore, Nanobiotix, AstraZeneca, Eisai, MSD, Seagen; Financial Interests, Institutional, Research Grant, Grant/Research Support Foundations: Prostate Cancer Foundation, San Salvatore Foundation; Financial Interests, Personal, Advisory Board, Consultation, fees, travel expenses: Johnson & Johnson, Seagen, MSD, BMS, AstraZeneca, Eisai; Non-Financial Interests, Institutional, Non-financial benefits, Academic Collaborations: EORTC chairman GCG, ESMO Scientific Committee member for drug development, ASTRO Scientific Committee Annual Meeting. A. Madariaga Urrutia: Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, Clovis, MSD; Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Presenter: Jitka Palich Fucikova
Session: Poster Display
182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer
Presenter: Louisa Hell
Session: Poster Display
183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_/EMT Modulation
Presenter: Songwei Feng
Session: Poster Display
184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.
Presenter: LUCIA CARRIL AJURIA
Session: Poster Display
185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma
Presenter: Yazan Al Zu’bi
Session: Poster Display
186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUcan sub-project
Presenter: Athénaïs Van Der Elst
Session: Poster Display
187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma
Presenter: Francesca Lucibello
Session: Poster Display
188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment
Presenter: Raya Leibowitz-Amit
Session: Poster Display
189P - The impact of immune microenvironment subopopulations on soft tissue sarcomas
Presenter: Shokhrukhbek Khujaev
Session: Poster Display